A patient-level analysis of efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine added to oral antidiabetes agents in people with type 2 diabetes

European Endocrinology

Volumn 10, Issue 1, 2014, Pages 23-30

  DeVries, J Hans ^a   Meneghini, Luigi ^b   Barnett, Anthony H ^c   Reid, Timothy ^d   Dain, Marie Paule ^e   Landgraf, Wolfgang ^f,g   Vlajnic, Aleksandra ^e   Traylor, Louise ^e   Bergenstal, Richard M ^h  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d Mercy Diabetes Center   (United States)

^e SANOFI   (France)

^f Sanofi   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h INTERNATIONAL DIABETES CENTER   (United States)

Author keywords

Insulin therapy; Metformin; Sulphonylurea; Type 2 diabetes

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; SULFONYLUREA;

ADD ON THERAPY; ADULT; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; DAYTIME HYPOGLYCEMIA; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SEVERE HYPOGLYCEMIA; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT GAIN;

EID: 84906502706     PISSN: 17583772     EISSN: 17583780     Source Type: Journal    
DOI: 10.17925/ee.2014.10.01.23     Document Type: Article

References (37)

1. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 1998;352:837-53.
2. Stratton IM, Adler AI, Neil HA, et al., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ, 2000;321:405-12.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al., American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD): Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 2012;35:1364-79.
4. Turner RC, Cull CA, Frighi V, Holman RR, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group, JAMA, 1999;281:2005-12.
5. Wright A, Burden AC, Paisey RB, et al., UK Prospective Diabetes Study Group: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57), Diabetes Care, 2002;25:330-6.
6. Swinnen SG, Dain MP, Mauricio D, et al., Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes, Diabetes Obes Metab, 2010;12:923-5.
7. Tenzer-Iglesias P, Shannon MH: Managing hypoglycemia in primary care, J Fam Pract, 2012;61(Suppl. 10):S1-S8.
8. Hayes RP, Fitzgerald JT, Jacober SJ, Primary care physician beliefs about insulin initiation in patients with type 2 diabetes, Int J Clin Pract, 2008;62:860-8.
9. Brunton SA, Davis SN, Renda SM, Overcoming psychological barriers to insulin use in type 2 diabetes, Clin Cornerstone, 2006;8(Suppl. 2):S19-26.
10. Nakar S, Yitzhaki G, Rosenberg R, Vinker S, Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers, J Diabetes Complications, 2007;21:220-6.
11. Peyrot M, Rubin RR, Lauritzen T, et al., International DAWN Advisory Panel: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study, Diabetes Care, 2005;28:2673-9.
12. Kruger DF, Intensifying insulin treatment: options, practical issues, and the role of the nurse practitioner, J Am Acad Nurse Pract, 2012;24(Suppl. 1):260-9.
13. Polonsky WH, Fisher L, Guzman S, et al., Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem, Diabetes Care, 2005;28:2543-5.
14. Seaquist ER, Anderson J, Childs B, et al., Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society, Diabetes Care, 2013;36:1384-95.
15. Swinnen SG, Mullins P, Miller M, et al., Changing the glucose cut- off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia, Diabetologia, 2009;52:38-41.
16. Bergenstal RM, Ahmann AJ, Bailey T, et al., Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: The Ambulatory Glucose Profile (AGP), Diabetes Technol Ther, 2013;15:198-211.
17. Mullins P, Sharplin P, Yki-Järvinen H, et al., Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus, Clin Ther, 2007;29:1607-19.
18. Henderson JN, Allen KV, Deary IJ, Frier BM, Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness, Diabet Med,2003;20:1016-21.
19. Leese GP, Wang J, Broomhall J, et al., Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use, Diabetes Care, 2003;26:1176-80.
20. UK Hypoglycaemia Study Group: Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration, Diabetologia, 2007;50:1140-7.
21. Bonds DE, Miller ME, Bergenstal RM, et al., The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study, BMJ, 2010;340:b4909.
22. Zoungas S, Patel A, Chalmers J, et al., Severe hypoglycemia and risks of vascular events and death, N Engl J Med, 2010;363:1410-8.
23. Brod M, Christensen T, Thomsen TL, Bushnell DM, The impact of non-severe hypoglycemic events on work productivity and diabetes management, Value Health, 2011;14:665-71.
24. Brod M, Pohlman B, Wolden M, Christensen T, Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being, Qual Life Res, 2013;22:997-1004.
25. Garber AJ, Hypoglycaemia: a therapeutic concern in type 2 diabetes, Lancet, 2012;379:2215-6.
26. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients, Diabetes Care, 2003;26:3080-6.
27. Rosenstock J, Sugimoto D, Strange P, et al., Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients, Diabetes Care, 2006;29:554-9.
28. Janka HU, Plewe G, Riddle MC, et al., Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes, Diabetes Care, 2005;28:254-9.
29. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al., Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study, Diabetologia, 2006;49:442-51.
30. Rosenstock J, Davies M, Home PD, et al., A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes, Diabetologia, 2008;51:408-16.
31. Fonseca V, Gill J, Zhou R, Leahy J, An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia, Diabetes Obes Metab, 2011;13:814-822.
32. Miller CD, Phillips LS, Ziemer DC, et al., Hypoglycemia in patients with type 2 diabetes mellitus, Arch Intern Med, 2001;161:1653-9.
33. Donnelly LA, Morris AD, Frier BM, et al., Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study, Diabet Med, 2005;22:749-55.
34. Lüddeke HJ, Sreenan S, Aczel S, et al., PREDICTIVE-a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort, Diabetes Obes Metab, 2007;9:428-34.
35. Davis TM, Brown SG, Jacobs IG, et al., Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study, J Clin Endocrinol Metab, 2010;95:2240-7.
36. Quilliam BJ, Simeone JC, Ozbay AB, Risk factors for hypoglycemia-related hospitalization in patients with type 2 diabetes: a nested case-control study, Clin Ther, 2011;33:1781-91.
37. Karl DM, Gill J, Zhou R, Riddle MC, Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus, Diabetes Obes Metab, 2013;15:622-8.